Chrono.gg

Chronos Therapeutics is a biotechnology company focused on developing therapies for neuropsychiatric and neurodegenerative diseases. Originally a spin-out from the University of Oxford, the company utilizes its proprietary platform to identify and develop small molecule candidates for brain-related disorders. Its pipeline features a class-leading Orexin-1 (Ox-1) antagonist targeting impulsivity and addiction, as well as an atypical dopamine transporter (DAT) inhibitor for fatigue and narcolepsy. In April 2024, Chronos was acquired by TheraCryf (formerly Evgen Pharma), integrating its assets into a broader portfolio of oncology and CNS treatments. The company's programs are currently in late pre-clinical development, with clinical entry anticipated in 2026.